IBDEI1AY ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23068,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,23069,0)
 ;;=V12.71^^125^1400^45
 ;;^UTILITY(U,$J,358.3,23069,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23069,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,23069,1,5,0)
 ;;=5^Hx of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,23069,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,23070,0)
 ;;=V10.46^^125^1400^48
 ;;^UTILITY(U,$J,358.3,23070,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23070,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,23070,1,5,0)
 ;;=5^Hx of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,23070,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,23071,0)
 ;;=V11.0^^125^1400^50
 ;;^UTILITY(U,$J,358.3,23071,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23071,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,23071,1,5,0)
 ;;=5^Hx of Schizophrenia
 ;;^UTILITY(U,$J,358.3,23071,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,23072,0)
 ;;=V10.83^^125^1400^51
 ;;^UTILITY(U,$J,358.3,23072,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23072,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,23072,1,5,0)
 ;;=5^Hx of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,23072,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,23073,0)
 ;;=V15.1^^125^1400^53
 ;;^UTILITY(U,$J,358.3,23073,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23073,1,4,0)
 ;;=4^V15.1
 ;;^UTILITY(U,$J,358.3,23073,1,5,0)
 ;;=5^Hx of Surgery To Heart And Great Vessels
 ;;^UTILITY(U,$J,358.3,23073,2)
 ;;=^295283
 ;;^UTILITY(U,$J,358.3,23074,0)
 ;;=V15.82^^125^1400^57
 ;;^UTILITY(U,$J,358.3,23074,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23074,1,4,0)
 ;;=4^V15.82
 ;;^UTILITY(U,$J,358.3,23074,1,5,0)
 ;;=5^Hx of Tobacco Use (not current)
 ;;^UTILITY(U,$J,358.3,23074,2)
 ;;=Hx of Tobacco Use (not current)^303405
 ;;^UTILITY(U,$J,358.3,23075,0)
 ;;=V12.01^^125^1400^54
 ;;^UTILITY(U,$J,358.3,23075,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23075,1,4,0)
 ;;=4^V12.01
 ;;^UTILITY(U,$J,358.3,23075,1,5,0)
 ;;=5^Hx of TB
 ;;^UTILITY(U,$J,358.3,23075,2)
 ;;=Hx of TB^303393
 ;;^UTILITY(U,$J,358.3,23076,0)
 ;;=V13.01^^125^1400^36
 ;;^UTILITY(U,$J,358.3,23076,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23076,1,4,0)
 ;;=4^V13.01
 ;;^UTILITY(U,$J,358.3,23076,1,5,0)
 ;;=5^Hx of Kidney Stones
 ;;^UTILITY(U,$J,358.3,23076,2)
 ;;=Hx of Kidney Stones^303403
 ;;^UTILITY(U,$J,358.3,23077,0)
 ;;=V12.51^^125^1400^59
 ;;^UTILITY(U,$J,358.3,23077,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23077,1,4,0)
 ;;=4^V12.51
 ;;^UTILITY(U,$J,358.3,23077,1,5,0)
 ;;=5^Hx of Venous Thrombosis And Embolism
 ;;^UTILITY(U,$J,358.3,23077,2)
 ;;=^303397
 ;;^UTILITY(U,$J,358.3,23078,0)
 ;;=V17.89^^125^1400^18
 ;;^UTILITY(U,$J,358.3,23078,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23078,1,4,0)
 ;;=4^V17.89
 ;;^UTILITY(U,$J,358.3,23078,1,5,0)
 ;;=5^Family h/o Musculosk Disease
 ;;^UTILITY(U,$J,358.3,23078,2)
 ;;=^332861
 ;;^UTILITY(U,$J,358.3,23079,0)
 ;;=V12.54^^125^1400^56
 ;;^UTILITY(U,$J,358.3,23079,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23079,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,23079,1,5,0)
 ;;=5^Hx of TIA
 ;;^UTILITY(U,$J,358.3,23079,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,23080,0)
 ;;=V12.54^^125^1400^52
 ;;^UTILITY(U,$J,358.3,23080,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23080,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,23080,1,5,0)
 ;;=5^Hx of Stroke w/o Residual
 ;;^UTILITY(U,$J,358.3,23080,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,23081,0)
 ;;=V15.88^^125^1400^33
 ;;^UTILITY(U,$J,358.3,23081,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23081,1,4,0)
 ;;=4^V15.88
 ;;^UTILITY(U,$J,358.3,23081,1,5,0)
 ;;=5^Hx of Fall(s)
 ;;
 ;;$END ROU IBDEI1AY
